Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 1998Journal of Clinical Oncology

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMark D. PegramStanford UniversityALA. LiptonBC Cancer AgencyDaniel F. HayesDaniel F. HayesIntermountain Healthcare

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pegram et al. (1998) studied this question.

synapsesocial.com/papers/69dff62e54cc5c1be0e9be5ehttps://doi.org/10.1200/jco.1998.16.8.2659
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.1990 · 86 citations
  2. 2Correlation of Intrinsic Chemoresistance of Non-Small-Cell Lung Cancer Cell Lines With HER-2/neu Gene Expression but Not With ras Gene Mutations1993 · 175 citations
  3. 3Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.1993 · 537 citations